Hot Topics in Tech | August 2018 Newsletter | Maxval

In this issue, we have covered a couple of hot topics that are currently trending in the biotech and blockchain technology industries. We have highlighted Illumina’s Q2 results and provided some insights about the company alongwith a quick run-through of the firm’s recent collaborations in China. Illumina reported a revenue of $830 million in Q2 which is a 25% increase compared to $662 million in the same quarter of 2017. Illumina’s biggest advantage over its competitors lies in its technology diversification. We have also discussed about Walmart, who aims to venture into transportation and logistics markets through a methodology (recently filed for patent) by

Continue reading »

Hot Topics in Tech | June 2018 Newsletter | Maxval

In this issue, we have covered a couple of hot topics that are currently trending in the biotech and cloud-tech industries. We have talked about the FDA’s approval of tisagenlecleucel (KYMRIAH, Novartis Pharmaceuticals Corp.), a CD19-directed genetically modified autologous T-cell immunotherapy, to include treatment of patients with relapsed or refractory large B-cell lymphoma. Tisagenlecleucel is the only CAR T-cell therapy to receive FDA approval for two distinct indications. The report includes a chart of major commercial players in the CAR T-cell space and a Year-on-Year trend on the number of patents and patent applications from 2012 to 2018. We have

Continue reading »

MaxVal to Sponsor and Exhibit at IPBC Global, San Francisco (June 10-12, 2018)

MaxVal is sponsoring the 11th annual event of IP Business Congress Global (IPBC), to be held from June 10-12, 2018 at Palace Hotel, San Francisco. IPBC is an established gathering for the World’s IP Business leaders ensuring extensive formal and informal networking opportunities. Its unrivaled coverage and in-depth analysis of key sectors provide executives critical business intelligence to maximize the IP value. As an exhibiting sponsor, MaxVal will demonstrate its end-to-end IP Management platform, Symphony, known for its robustness, reliability, and automation in handling the complete IP lifecycle. “I’m proud to be a part of the company that has created Symphony

Continue reading »

MaxVal Exhibits at INTA 140th Annual Meeting, Seattle, WA (May 19-23, 2018)

MaxVal is exhibiting at INTA 140th Annual meeting at Booth #418, to be held from May 19-23 at Washington State Convention Center, Seattle, WA. INTA’s (International Trademark Association) Annual Meeting is recognized as one of the premier events for the trademark industry which is expected to attract more than 10,000 attendees from around the world. Brand owners, in-house counsel, law firms, government officials, and other IP experts will gather in this 140th annual meeting to discuss and examine the key industry issues, challenges, and opportunities in the ever-growing IP landscape. MaxVal, a preferred IP management partner for law firms and

Continue reading »

Arista Wins Copyright and Patent Battle with Cisco

Recently, Arista Networks won a major ruling in the long-running patent and copyright clash with Cisco. A jury in San Jose, California federal court found that Arista owed no damages over Cisco’s claims of patent infringement. Additionally, the jurors also found that Arista did not infringe Cisco’s patent as well. Initially, in 2014 Cisco sued Arista for infringing its copyright and patent which included Cisco Internetwork Operating System (IOS) 11.0, Cisco IOS 11.1 and Cisco IOS 11.2. Further, Cisco named one patent in the suit, US number 7,047,526, titled “Generic command interface for multiple executable routines”. Cisco was roughly seeking

Continue reading »